Parabilis Medicines, Inc.
Parabilis Medicines, Inc. is a U.S.-based clinical-stage biopharmaceutical company developing medicines against disease-driving protein targets that have historically been difficult to address with conventional drugs. Its proprietary Helicons platform uses stabilized helical peptides, with programs including zolucatetide for rare solid tumors and research aimed at severe rare genetic diseases.
Liiketoiminta
Osuus liikevaihdostaResearch activities conducted for partners under license and collaboration agreements.
Clinical development of zolucatetide for desmoid tumors and other rare solid tumors.
Proprietary stabilized peptide technology for binding and modulating difficult protein targets.
Discovery and development activities targeting severe rare genetic diseases.
Asiakkaat
Parabilis currently operates primarily as a development-stage biotechnology company rather than a commercial pharmaceutical supplier, and it has not generated product revenue. Its principal commercial counterparties are biopharmaceutical collaborators such as Regeneron, which may fund research, license technology, or support future development. Future customers could include healthcare providers, specialty pharmacies, and patients whose treatments receive regulatory approval and reimbursement.
Companies seeking access to Helicons technology, discovery programs, or partnered research capabilities.
Current partner funding research on collaboration targets under the Regeneron Agreement.
Specialist physicians and treatment centers that could administer approved zolucatetide therapies.
Specialty pharmacies, payors, and providers supporting future genetic-disease treatments.
Strategia
Parabilis is prioritizing clinical development of zolucatetide and evaluation of additional indications, including FAP, HCC, and other rare solid tumors. It is also advancing the Helicons platform and rare genetic disease research while using collaborations such as the Regeneron Agreement to extend research capabilities and funding. Future commercialization will depend on regulatory approvals, manufacturing readiness, reimbursement, and either internal sales capabilities or third-party distribution partnerships.
Clinical validation is required before the lead program can produce product revenue.
Additional rare-disease indications could increase the addressable market if supported by clinical data.
The platform is intended to address protein targets beyond the reach of conventional medicines.
Partners can provide research funding, development capabilities, and future commercialization support.
Maantiede
Parabilis is headquartered and incorporated in the United States, where its corporate, research, clinical-development, and public-company activities are centered. Its development model relies on external contract research and manufacturing organizations, clinical sites, and potential commercial partners that may operate across multiple countries. The reported excerpts do not provide country-level revenue or a regional revenue distribution, and the company has not generated product sales.
Riskit
Parabilis faces the core risks of clinical-stage biotechnology: candidates may fail to demonstrate efficacy or safety, obtain regulatory approval, secure reimbursement, or achieve commercial adoption. Its dependence on external manufacturers, research providers, collaborators, and future sales partners creates execution and control risks, while competition from better-funded companies may delay or reduce market access. The company also has no approved products and must continue funding substantial research, clinical, regulatory, and commercialization activities before product revenue can become meaningful.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen
Trials may fail to show adequate efficacy or acceptable safety, preventing approval and product revenue.
Kohdistuu: Zolucatetide and future Helicons candidates
- Regulatory and reimbursement uncertaintyVaikutus: KorkeaTodennäköisyys: Kohtalainen
FDA approval, payer coverage, discounts, and reimbursement levels determine whether future products can be commercialized.
Kohdistuu: All future approved products
- Manufacturing and supply-chain executionVaikutus: KorkeaTodennäköisyys: Kohtalainen
Contract manufacturing defects, capacity constraints, raw-material failures, or cold-chain problems could interrupt clinical supply.
Kohdistuu: CMOs and future commercial supply
- Dependence on collaborators and commercialization partnersVaikutus: KorkeaTodennäköisyys: Kohtalainen
Partners may not provide sufficient resources or may be unavailable on favorable terms, limiting development and sales execution.
Kohdistuu: Regeneron and future licensing or distribution relationships
- Competitive pressureVaikutus: KorkeaTodennäköisyys: Kohtalainen
Larger pharmaceutical and biotechnology companies may have greater capital, technology, regulatory experience, and commercial reach.
Kohdistuu: Rare tumors and genetic disease markets
- Capital requirementsVaikutus: KorkeaTodennäköisyys: Matala
The company has no commercial product base and must fund research, trials, regulatory work, manufacturing, and infrastructure.
Kohdistuu: Ongoing operations before product commercialization
Kirjanpito
Harkinnanvaraiset erätRevenue is recognized as research obligations are performed rather than necessarily when cash is received.
Vaikutus: Quarterly revenue may differ from collaboration cash inflows.
Regeneron research revenue is measured using costs incurred relative to estimated costs to complete.
Vaikutus: Changes in forecast costs can accelerate or defer reported revenue.
Development, regulatory, and commercial milestones are variable consideration subject to recognition constraints.
Vaikutus: Future revenue timing may be volatile and dependent on clinical and regulatory outcomes.
Clinical, CRO, CMO, and scientific-service costs often require estimates before final invoices are received.
Vaikutus: Accrual revisions can affect reported operating expenses and net loss.
The simple agreement for future equity is remeasured and can generate non-operating gains or losses.
Vaikutus: Net income can fluctuate independently of operating performance.
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Relay Therapeutics, Inc.
RLAY · Biological Products, (No Diagnostic Substances)
Praxis Precision Medicines, Inc.
PRAX · Pharmaceutical Preparations
Amicus Therapeutics, Inc.
Pharmaceutical Preparations
SELLAS Life Sciences Group, Inc.
SLS · Pharmaceutical Preparations
SELLAS Life Sciences Group is a U.S.-based late-stage clinical biopharmaceutical company focused on developing cancer therapeutics.
Kalaris Therapeutics, Inc.
KLRS · Biological Products, (No Diagnostic Substances)
Supernus Pharmaceuticals, Inc
SUPN · Pharmaceutical Preparations
Supernus Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing medicines for central nervous system diseases.
Päivitetty: 24.9.2026